Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Find Out the Optimal Dose of Caffeine in the Combination Tablet of Naproxen Sodium and Caffeine in Patients Experiencing Moderate to Severe Pain After Having Wisdom Teeth Removed

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04132336
Recruitment Status : Not yet recruiting
First Posted : October 18, 2019
Last Update Posted : November 13, 2019
Sponsor:
Information provided by (Responsible Party):
Bayer

Brief Summary:
The researchers in this study want to find out the optimal dose of Caffeine in the combination tablet of Naproxen Sodium and Caffeine that works in patients experiencing moderate to severe pain after having wisdom teeth removed. In the US, Naproxen has been marketed since 1976, and Naproxen Sodium has been approved for over-the-counter (OTC) use since 1994 for the temporary relief of minor aches and pains. Caffeine, which is generally consumed as coffee, tea or cocoa, has been shown to enhance the effectiveness of various pain relievers, and therefore is accepted as an additive to painkillers like aspirin and acetaminophen. Patients participating in this study will undergo a surgery to remove 3 or 4 wisdom teeth. If the pain severity after the surgery meets the study requirement, patients will receive oral tablet(s) of Naproxen Sodium and Caffeine, or Naproxen Sodium, or Caffeine, or placebo (drug with no active ingredient). Patients can also receive additional pain medication when needed. Researchers will also learn if the patients have any medical problems during the study.

Condition or disease Intervention/treatment Phase
Pain, Postoperative Drug: Naproxen sodium/Caffeine (BAY2880376) Drug: Naproxen sodium (Aleve) Drug: Caffeine Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 190 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Single-Dose, Parallel, Placebo-Controlled Trial to Determine the Dose of Caffeine in a Fixed Dose Combination Tablet of Naproxen Sodium and Caffeine to Effectively Alleviate Postsurgical Dental Pain
Estimated Study Start Date : November 11, 2019
Estimated Primary Completion Date : May 2, 2020
Estimated Study Completion Date : May 2, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Caffeine

Arm Intervention/treatment
Experimental: Naproxen sodium/caffeine - Dose 1
Participants will receive one tablet of naproxen sodium/caffeine at dose 1 plus one tablet of placebo after extraction of third molars
Drug: Naproxen sodium/Caffeine (BAY2880376)
Tablet, oral, single dose

Experimental: Naproxen sodium/caffeine - Dose 2
Participants will receive one tablet of naproxen sodium/caffeine at dose 2 plus one tablet of placebo after extraction of third molars
Drug: Naproxen sodium/Caffeine (BAY2880376)
Tablet, oral, single dose

Experimental: Naproxen sodium/caffeine - Dose 3
Participants will receive two tablets of naproxen sodium/caffeine at dose 3 after extraction of third molars
Drug: Naproxen sodium/Caffeine (BAY2880376)
Tablet, oral, single dose

Experimental: Naproxen sodium/caffeine - Dose 4
Participants will receive two tablets of naproxen sodium/caffeine at dose 4 after extraction of third molars
Drug: Naproxen sodium/Caffeine (BAY2880376)
Tablet, oral, single dose

Active Comparator: Naproxen sodium
Participants will receive one tablet of naproxen sodium plus one tablet of placebo after extraction of third molars
Drug: Naproxen sodium (Aleve)
Tablet, oral, single dose

Active Comparator: Caffeine
Participants will receive two tablets of caffeine after extraction of third molars
Drug: Caffeine
Tablet, oral, single dose

Placebo Comparator: Placebo
Participants will receive two tablets of matching placebo after extraction of third molars
Drug: Placebo
Tablet, oral, single dose




Primary Outcome Measures :
  1. Sum of pain intensity difference (SPID) over 8 hours [ Time Frame: Up to 8 hours post dose ]
    Pain intensity is measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). For each post dose time point, pain intensity difference (PID) is derived by subtracting the pain intensity at the post dose time point from the baseline intensity score (baseline score - post-baseline score).


Secondary Outcome Measures :
  1. Sum of pain intensity difference (SPID) over 2 hours [ Time Frame: Up to 2 hours post dose ]
    Pain intensity is measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). For each post dose time point, pain intensity difference (PID) is derived by subtracting the pain intensity at the post dose time point from the baseline intensity score (baseline score - post-baseline score).

  2. Sum of pain intensity difference (SPID) over 4 hours [ Time Frame: Up to 4 hours post dose ]
    Pain intensity is measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). For each post dose time point, pain intensity difference (PID) is derived by subtracting the pain intensity at the post dose time point from the baseline intensity score (baseline score - post-baseline score).

  3. Sum of pain intensity difference (SPID) over 12 hours [ Time Frame: Up to 12 hour post dose ]
    Pain intensity is measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). For each post dose time point, pain intensity difference (PID) is derived by subtracting the pain intensity at the post dose time point from the baseline intensity score (baseline score - post-baseline score).

  4. Total pain relief (TOTPAR) over 2 hours [ Time Frame: Up to 2 hours post dose ]
    Pain relief is measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief). Total Pain Relief is calculated as the area under the curve of pain relief score over time for the given time period by multiplying the pain relief score at each time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period.

  5. Total pain relief (TOTPAR) over 4 hours [ Time Frame: Up to 4 hours post dose ]
    Pain relief is measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief). Total Pain Relief is calculated as the area under the curve of pain relief score over time for the given time period by multiplying the pain relief score at each time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period.

  6. Total pain relief (TOTPAR) over 8 hours [ Time Frame: Up to 8 hours post dose ]
    Pain relief is measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief). Total Pain Relief is calculated as the area under the curve of pain relief score over time for the given time period by multiplying the pain relief score at each time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period.

  7. Total pain relief (TOTPAR) over 12 hours [ Time Frame: Up to 12 hours post dose ]
    Pain relief is measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief). Total Pain Relief is calculated as the area under the curve of pain relief score over time for the given time period by multiplying the pain relief score at each time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period.

  8. Time (hours) to first use of rescue medication [ Time Frame: Up to 12 hours post dose ]
  9. Percentage of participants taking rescue medication [ Time Frame: Up to 12 hours post dose ]
  10. Time (hours) to first perceptible relief measured by a stopwatch [ Time Frame: Up to 12 hours post dose ]
  11. Time (hours) to meaningful relief measured by a stopwatch [ Time Frame: Up to 12 hours post dose ]
  12. Time (hours) to first perceptible relief confirmed by meaningful relief [ Time Frame: Up to 12 hours ]
    Time to first perceptible relief confirmed by meaningful relief is defined as the time to perceptible pain relief (the first stopwatch time) for those participants who had meaningful pain relief (the second stopwatch time)

  13. Pain Intensity Difference (PID) at each evaluation [ Time Frame: Up to 12 hours post dose ]
    Pain intensity is measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). For each post dose time point, pain intensity difference (PID) is derived by subtracting the pain intensity at the post dose time point from the baseline intensity score (baseline score - post-baseline score).

  14. Pain relief score at each evaluation [ Time Frame: Up to 12 hours post dose ]
    Pain relief is measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief)

  15. Peak pain intensity difference (PID) [ Time Frame: Up to 12 hours post dose ]
    Pain intensity is measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). For each post dose time point, pain intensity difference (PID) is derived by subtracting the pain intensity at the post dose time point from the baseline intensity score (baseline score - post-baseline score).

  16. Peak pain relief score [ Time Frame: Up to 12 hours post dose ]
    Pain relief is measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief)

  17. Percentage of participants with at least a 2-point PID [ Time Frame: Up to 12 hours post dose ]
  18. Global assessment of the investigational product [ Time Frame: Up to 12 hours post dose ]
    Global assessment is performed either at 12 hours post-dose or immediately prior to the first intake of rescue medication. Global assessment is based on the question 'Overall, I would rate the study medication I received: 0=Poor, 1=Fair, 2=Good, 3=Very Good, 4=Excellent.'

  19. Number of participants with adverse events (AE) [ Time Frame: Up to 5 days post dose ]
  20. Number of subjects with clinically significant changes in physical examinations, vital signs or laboratory assessments [ Time Frame: Up to 5 days post dose ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Healthy, ambulatory, male or female volunteers 16 years of age or older;
  • Body mass index (BMI) 18.5 to 35.0 kg/m^2 inclusive as measured by the National Institutes of Health (NIH) BMI Calculator;
  • Participants will undergo surgical extraction of three or four third molars, two of which must be mandibular molars. Maxillary third molars may be removed regardless of impaction level. The mandibular extractions must have a trauma rating of mild or moderate and meet one of the following scenarios: two full bony impactions; two partial bony impactions; one full bony impaction in combination with one partial bony impaction. supernumerary teeth present may also be removed at the discretion of the oral surgeon;
  • Have not taken any form of medication, nutritional supplements with analgesic properties (e.g. gamma-Aminobutyric acid [GABA], turmeric) or herbal supplements (i.e., St. John's Wort) within 5 days of admission (except for oral contraceptives, prophylactic antibiotics, multivitamin supplements, or other routine medications to treat benign conditions (such as antibiotics to treat acne), and agree not to take any medication (other than that provided to them) throughout the study;
  • Use of only short-acting local anesthetic (e.g., mepivacaine or lidocaine) preoperatively, with or without a vasoconstrictor and nitrous oxide at the discretion of the Investigator;
  • Have moderate to severe postoperative pain on the Categorical Pain Intensity Scale (a score of at least 2 on a 4 point scale) and a score of ≥ 5 on the 0-10 pain intensity Numerical Rating Scale (NRS) within 4.5 hours post-surgery.

Exclusion Criteria:

  • History of hypersensitivity to naproxen sodium, caffeine, ibuprofen, nonsteroidal anti-inflammatory drug (NSAIDS), aspirin, similar pharmacological agents, local anesthetics, rescue medication or components of the investigational products;
  • Evidence or history of clinically significant (in the judgment of the investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular (including hypertension and cardiac arrhythmia), hepatic, psychiatric, neurologic diseases, or malignancies within the last 5 years;
  • Participants with the following medical conditions may be eligible at the discretion of the investigator: attention deficit hyperactivity disorder (ADHD) on a stable dose regimen of methylphenidate/(dextro) amphetamine for at least 6 months; participants with hypothyroidism on a stable dose of synthetic thyroid hormone for at least 6 months;
  • Have received any form of treatment in the form of medication for depression in the past 6 months or any form of psychotropic agent (including selective serotonin uptake inhibitors [SSRI] but excluding ADHD medications described above) within the last 6 months;
  • Relevant concomitant disease such as asthma (exercise induced asthma is permitted);
  • Current or past history of gastrointestinal ulceration, gastrointestinal bleeding or other bleeding disorder(s);
  • Acute illness or active local infection prior to surgery that can interfere with the conduct of the study in the judgment of the investigator;
  • Use of any over-the-counter (OTC) or prescription medications with which the administration of naproxen, acetaminophen, ibuprofen, any other NSAID, (e.g., tramadol) or if a medication is contraindicated;
  • Use of any medications within 5 days of surgery until discharge from the study site (except oral contraceptives, prophylactic antibiotics, synthetic thyroid hormones, methylphenidate or medications to treat benign conditions such as antibiotics to treat acne);
  • Use of caffeine within 2 days prior to the study;
  • Habits of high consumption of caffeine (>400 mg/day equivalent to about 3-4 cups of coffee per day);
  • Habituation to analgesic drugs including opioids (i.e., routine use of oral analgesics 5 or more times per week for greater than 3 weeks within the past 2 years);
  • Surgeon's trauma rating of severe following surgery.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04132336


Contacts
Layout table for location contacts
Contact: Bayer Clinical Trials Contact (+)1-888-84 22937 clinical-trials-contact@bayer.com

Sponsors and Collaborators
Bayer

Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT04132336     History of Changes
Other Study ID Numbers: 21069
2019-003513-33 ( EudraCT Number )
First Posted: October 18, 2019    Key Record Dates
Last Update Posted: November 13, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bayer:
Dental pain
Additional relevant MeSH terms:
Layout table for MeSH terms
Pain, Postoperative
Postoperative Complications
Pathologic Processes
Pain
Neurologic Manifestations
Signs and Symptoms
Naproxen
Caffeine
Central Nervous System Stimulants
Physiological Effects of Drugs
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Anti-Inflammatory Agents
Antirheumatic Agents
Gout Suppressants
Cyclooxygenase Inhibitors